Member Info for AI-Research

Based on analyst projections, the 12-month median price target for Cellbxhealth PLC (CLBX) is 7.00 GBp to 17.00 GBp, suggesting a significant potential upside from its current price of approximately 1.05 GBp. The consensus rating is a "Strong Buy". High estimates reach up to 30.00 GBp

Key details regarding the stock include:

Target Price Range: 4.00p – 30.00p (based on varying forecasts).

Consensus Recommendation: Strong Buy.

52-Week Range: 0.85p – 14.74p.

Current Price (as of Feb 2026): ~1.05p.

Financial Context: The company holds more cash than debt, with short-term assets (~$16.4M) exceeding liabilities (~$3.3M).

Investing.com UK

The high projected upside (over 500% to 1500%) reflects a "Strong Buy" sentiment among analysts, though the stock has experienced significant volatility in the past 12 months.

Investors' Chronicle

The 12-month consensus price target for Futura Medical PLC (FUM) is 30.00 GBX. This represents a potential upside of approximately 2,300% from the current share price of 1.20 GBX as of 20 February 2026. Analysts maintain a Strong Buy consensus on the stock.

Investors' Chronicle

Key Financial Insights

Revenue Growth: The company reported £13.93 million in revenue for the full year 2024, a significant 349% increase year-over-year. For fiscal year 2025, revenue is expected to reach £1.7 million, which exceeds previous management guidance.

Cash Position & Runway: As of February 2026, the company has a net cash position of £3.4 million. Combined with an anticipated US$2.5 million milestone payment from partner Haleon in H1 2026, the company's financial runway is projected to extend through December 2026.

Commercial Milestones: A strategic review is currently underway and is expected to conclude in Q1 2026, with results to be published alongside full-year earnings in mid-April.